Search

Your search keyword '"Hurtado, Kimberly"' showing total 10 results
Start Over Author "Hurtado, Kimberly"
10 results on '"Hurtado, Kimberly"'

2. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J., Mullane, Kathleen M., Cornely, Oliver A., Boeckh, Michael J., Brown, Janice Wes, Pergam, Steven A., Trociukas, Igoris, Zak, Pavel, Craig, Michael D., Papanicolaou, Genovefa A., Velez, Juan D., Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A., Stek, Jon E., Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S. F., Kaplan, Susan S., Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W., Arvin, Ann, Winston, Drew J., Mullane, Kathleen M., Cornely, Oliver A., Boeckh, Michael J., Brown, Janice Wes, Pergam, Steven A., Trociukas, Igoris, Zak, Pavel, Craig, Michael D., Papanicolaou, Genovefa A., Velez, Juan D., Panse, Jens, Hurtado, Kimberly, Fernsler, Doreen A., Stek, Jon E., Pang, Lei, Su, Shu-Chih, Zhao, Yanli, Chan, Ivan S. F., Kaplan, Susan S., Parrino, Janie, Lee, Ingi, Popmihajlov, Zoran, Annunziato, Paula W., and Arvin, Ann

Abstract

Background Recipients of autologous haemopoietic stem-cell transplants (auto-HSCT) have an increased risk of herpes zoster and herpes zoster-related complications. The aim of this study was to establish the efficacy and safety of an inactivated varicella zoster vaccine for the prevention of herpes zoster after auto-HSCT. Methods In this randomised, double-blind, placebo-controlled phase 3 trial, participants were recruited from 135 medical centres (ie, stem-cell transplant centres and hospitals) in North America, South America, Europe, and Asia. Patients were eligible if they were aged 18 years or older, scheduled to receive an auto-HSCT within 60 days of enrolment, and had a history of varicella infection or were seropositive for antibodies to varicella zoster virus, or both. Exclusion criteria included a history of herpes zoster within the previous year of enrolment, and intended antiviral prophylaxis for longer than 6 months after transplantation. Participants were randomly assigned according to a central randomisation schedule generated by the trial statistician, to receive either the inactivated-virus vaccine from one of three consistency lots, a high-antigen lot, or placebo, stratified by age (< 50 vs >= 50 years) and intended duration of antiviral prophylaxis after transplantation (<= 3 months vs > 3 to <= 6 months). Participants, investigators, trial staff, and the funder's clinical and laboratory personnel were masked to group assignment. Participants were given four doses of inactivated vaccine or placebo, with the first dose 5-60 days before auto-HSCT, and the second, third, and fourth doses at about 30, 60, and 90 days after transplantation. The primary efficacy endpoint was the incidence of herpes zoster, confirmed by PCR or adjudication by a masked clinical committee, or both, assessed in all participants randomly assigned to the vaccine consistency lot group or placebo group who received at least one dose of vaccine and had auto-HSCT. Safety was asses

Published
2018

3. Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer.

Author

Boeckh, Michael J, Arvin, Ann M, Mullane, Kathleen M, Camacho, Luis H, Winston, Drew J, Morrison, Vicki A, Hurtado, Kimberly, Hall, Jessie Durrand, Pang, Lei, Su, Shu-Chih, Kaplan, Susan S, Annunziato, Paula W, Popmihajlov, Zoran, and Group, V212 Protocol 001 Trial Group and V212 Protocol 011 Trial

Subjects
HEMATOPOIETIC stem cells, STEM cell transplantation, HERPES zoster vaccines, VARICELLA-zoster virus diseases, HERPES zoster, CHICKENPOX, CLINICAL trial registries
Abstract

Background In phase 3 trials, inactivated varicella zoster virus (VZV) vaccine (ZVIN) was well tolerated and efficacious against herpes zoster (HZ) in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and patients with solid tumor malignancies receiving chemotherapy (STMc) but did not reduce HZ incidence in patients with hematologic malignancies (HMs). Here, we describe ZVIN immunogenicity from these studies. Methods Patients were randomized to ZVIN or placebo (4 doses). Immunogenicity was assessed by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and VZV interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) assay in patients receiving all 4 doses without developing HZ at the time of blood sampling. Results Estimated geometric mean fold rise ratios (ZVIN/placebo) by gpELISA and IFN-y ELISPOT ~28 days post–dose 4 were 2.02 (95% confidence interval [CI], 1.53–2.67) and 5.41 (95% CI, 3.60–8.12) in auto-HSCT recipients; 1.88 (95% CI, 1.79–1.98) and 2.10 (95% CI, 1.69–2.62) in patients with STMc; and not assessed and 2.35 (95% CI, 1.81–3.05) in patients with HM. Conclusions ZVIN immunogenicity was directionally consistent with clinical efficacy in auto-HSCT recipients and patients with STMc even though HZ protection and VZV immunity were not statistically correlated. Despite a lack of clinical efficacy in patients with HM, ZVIN immunogenicity was observed in this population. Immunological results did not predict vaccine efficacy in these 3 populations. Clinical trial registration NCT01229267, NCT01254630. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

4. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

Author

Winston, Drew J, primary, Mullane, Kathleen M, additional, Cornely, Oliver A, additional, Boeckh, Michael J, additional, Brown, Janice Wes, additional, Pergam, Steven A, additional, Trociukas, Igoris, additional, Žák, Pavel, additional, Craig, Michael D, additional, Papanicolaou, Genovefa A, additional, Velez, Juan D, additional, Panse, Jens, additional, Hurtado, Kimberly, additional, Fernsler, Doreen A, additional, Stek, Jon E, additional, Pang, Lei, additional, Su, Shu-Chih, additional, Zhao, Yanli, additional, Chan, Ivan S F, additional, Kaplan, Susan S, additional, Parrino, Janie, additional, Lee, Ingi, additional, Popmihajlov, Zoran, additional, Annunziato, Paula W, additional, Arvin, Ann, additional, Basso, AC, additional, Bonvehi, P, additional, Cerana, S, additional, Dictar, MO, additional, Campbell, P, additional, Playford, G, additional, Sasadeusz, J, additional, Maertens, J, additional, Poire, X, additional, Sellesag, D, additional, Schots, R, additional, Theunissen, K, additional, Willems, E, additional, Alves, RS, additional, Camargo, JFC, additional, Castro, NS, additional, Maria Fogliatto, L, additional, Rodrigo, O, additional, Courture, F, additional, McGeer, A, additional, Miller, M, additional, Combariza, JF, additional, Sossa, CL, additional, Velez, JD, additional, Nemet, D, additional, Ostojic Kolonic, S, additional, Jebavy, L, additional, Mayer, J, additional, Novak, J, additional, Pohlreich, D, additional, Maldonado, B, additional, Gastinne, T, additional, Karlin, L, additional, Launay, O, additional, Cornely, OA, additional, Duerk, HA, additional, Haenel, M, additional, Heinz, W, additional, Kaufmann, M, additional, Panse, J, additional, Teschner, D, additional, Verbeek, M, additional, Wulf, G, additional, Aviv, F, additional, Grisariu, S, additional, Nagler, A, additional, Yeshurun, M, additional, Bosi, A, additional, Corradini, P, additional, Martinelli, G, additional, Onida, F, additional, Rambaldi, A, additional, Velardi, A, additional, Trociukas, I, additional, Gomez, AD, additional, Wondergem, MJ, additional, Ypma, PF, additional, Fanilla, E, additional, Moreno Larrea, MDC, additional, Abecasis, MM, additional, Ferreira, RB, additional, Geraldes, C, additional, Castro, J, additional, Afanasyev, BV, additional, Kruchkova, IV, additional, Zaritskiy, AY, additional, Cheong, JW, additional, Kim, SJ, additional, Lee, DG, additional, Yoon, SS, additional, Aguado Bueno, B, additional, Jarque Ramos, I, additional, Solano Vercet, C, additional, Cherif, H, additional, Ljungman, P, additional, Vaht, K, additional, Cook, G, additional, Kanfer, E, additional, Milligan, DW, additional, Parker, A, additional, Akard, L, additional, Bachier, C, additional, Ball, ED, additional, Betts, FR, additional, Braunschweig, I, additional, Brown, JM, additional, Carroll, MP, additional, Chandrasekar, PH, additional, Collins, R, additional, Cooper, B, additional, Craig, M, additional, D'Cunha, N, additional, Donato, ML, additional, Essell, J, additional, Flomenberg, P, additional, Freifeld, A, additional, Freytes, C, additional, Guarino, MJ, additional, Hall, MC, additional, Heimenz, JW, additional, High, KP, additional, Isola, LM, additional, Kaminer, L, additional, Klein, LM, additional, Janakiraman, N, additional, Kane, K, additional, Komanduri, K, additional, Krijanovski, OI, additional, Lawrence, SJ, additional, Leis, JF, additional, Lill, M, additional, Longo, WL, additional, Lynch, JP, additional, Mattar, BI, additional, Mehta, J, additional, Mullane, KM, additional, Nathan, S, additional, Papanicolaou, GA, additional, Pergam, SA, additional, Roy, V, additional, Rybka, W, additional, Safah, H, additional, Saltzman, D, additional, Segal, GM, additional, Selby, GB, additional, Schuster, MW, additional, Shoham, S, additional, Sloan, JM, additional, Strasfeld, LM, additional, Styler, M, additional, Sullivan, K, additional, Tse, W, additional, Vance, EA, additional, Winston, DJ, additional, and Yanovich, S, additional

Published
2018
Full Text
View/download PDF

5. BIM comes of age: the new consensus DOCs BIM Addendum (2015) for life-cycle building information modeling.

Author

Hurtado, Kimberly A.

Subjects
3D printing -- Laws, regulations and rules, Construction industry -- Laws, regulations and rules -- Models, Computer-aided design -- Usage, Government regulation
Abstract

A decade ago, building information modeling (BIM) software was becoming commercially available in the United States to create three dimensional (3D) images of structures. There were no best practices for [...]

Published
2016

6. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated Vzv Vaccine (ZVIN) in Recipients of Autologous Hematopoietic Cell Transplants (Auto-Hcts)

Author

Winston, Drew J., Mullane, Kathleen M., Boeckh, Michael J., Cornely, Oliver A., Hurtado, Kimberly, Su, Shu-Chih, Pang, Lei, Zhao, Yanli, Chan, Ivan S. F., Stek, Jon E., Kaplan, Susan S., Parrino, Janie, Annunziato, Paula, Popmihajlov, Zoran, Arvin, Ann, Winston, Drew J., Mullane, Kathleen M., Boeckh, Michael J., Cornely, Oliver A., Hurtado, Kimberly, Su, Shu-Chih, Pang, Lei, Zhao, Yanli, Chan, Ivan S. F., Stek, Jon E., Kaplan, Susan S., Parrino, Janie, Annunziato, Paula, Popmihajlov, Zoran, and Arvin, Ann

Published
2017

7. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated Vzv Vaccine (ZVIN) in Recipients of Autologous Hematopoietic Cell Transplants (Auto-Hcts)

Author

Winston, Drew J., primary, Mullane, Kathleen M., additional, Boeckh, Michael J., additional, Cornely, Oliver A., additional, Hurtado, Kimberly, additional, Su, Shu-Chih, additional, Pang, Lei, additional, Zhao, Yanli, additional, Chan, Ivan S.F., additional, Stek, Jon E., additional, Kaplan, Susan S., additional, Parrino, Janie, additional, Annunziato, Paula, additional, Popmihajlov, Zoran, additional, and Arvin, Ann, additional

Published
2017
Full Text
View/download PDF

8. 6 - A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of Inactivated Vzv Vaccine (ZVIN) in Recipients of Autologous Hematopoietic Cell Transplants (Auto-Hcts)

Author

Winston, Drew J., Mullane, Kathleen M., Boeckh, Michael J., Cornely, Oliver A., Hurtado, Kimberly, Su, Shu-Chih, Pang, Lei, Zhao, Yanli, Chan, Ivan S.F., Stek, Jon E., Kaplan, Susan S., Parrino, Janie, Annunziato, Paula, Popmihajlov, Zoran, and Arvin, Ann

Published
2017
Full Text
View/download PDF

9. Developing Meaningful Contract Terms for Electronic Communications on Construction Projects.

Author

Ashcraft, Howard W. and Hurtado, Kimberly A.

Subjects
BUILDING information modeling, CONSTRUCTION projects, MANAGEMENT of information resources in construction industry, INFORMATION resources management, INFORMATION resources, INFORMATION technology, COMPUTER network resources
Abstract

The article reports on the different contract forms that need to be considered in the utilization of electronic communications for construction projects in the U.S. These include the contract documents of the Engineers Joint Contract Documents Committee (EJCDC), ConsensusDOCS Electronic Communications Protocol Addendum (ECP Addendum), and Building Information Modeling (BIM) Protocol Exhibit. Information on the legal issues involved in project electronic communications is also discussed.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results